Related Experiment Video
Updated: Apr 7, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis
Torjan Haslerud1, Katrin Brauckhoff2, Lars Reisæter3
1Nuclear Medicine/PET-Center, Department of Radiology, Haukeland University Hospital, Bergen, Norway.
Background:
Positron emission tomography (PET) with fluor-18-deoxy-glucose (FDG) is widely used for diagnosing recurrent or metastatic disease in patients with differentiated thyroid cancer (DTC).
Purpose:
To assess the diagnostic accuracy of FDG-PET for DTC in patients after ablative therapy.
Material And Methods:
A systematic search was conducted in Medline/PubMed, EMBASE, Cochrane Library, Web of Science, and Open Grey looking for all English-language original articles on the performance of FDG-PET in series of at least 20 patients with DTC having undergone ablative therapy including total thyroidectomy. Diagnostic performance measures were pooled using Reitsma's bivariate model.
Results:
Thirty-four publications between 1996 and 2014 met the inclusion criteria. Pooled sensitivity and specificity were 79.4% (95% confidence interval [CI], 73.9-84.1) and 79.4% (95% CI, 71.2-85.4), respectively, with an area under the curve of 0.858.
Conclusion:
F18-FDG-PET is a useful method for detecting recurrent DTC in patients having undergone ablative therapy.
More Related Videos
10:02Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT
Published on: May 2, 2012
03:55Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023